UP!
 |
|
|
Type
|
Public (NASDAQ: BCRX) |
|---|---|
| Industry | Healthcare |
| Founded | 1986 |
| Headquarters | Durham, North Carolina, USA |
|
Key people
|
Jon P. Stonehouse , President and Chief Executive Officer Thomas Staab II, Chief Financial Officer |
| Products | Biotechnology |
| Revenue |  US$26.3M (FY 2012) |
|
Operating income
|
 US$-33.9M (FY 2012) |
|
Net income
|
US$-39.1M (FY 2012) |
| Total assets | US$57.4M (FY 2012) |
| Total equity | US$-0.4M (FY 2012) |
|
Number of employees
|
37 (2013) |
| Website | www.biocryst.com |
BioCryst Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Durham, North Carolina. The company focuses on orphan & autoimmune diseases, and antivirals. The company's most advanced drug candidate is the antiviral Peramivir, which is approved in Japan, Korea and China. It was authorized by the FDA for emergency use in the treatment of patients hospitalized with influenza during the 2009-10 influenza A virus subtype H1N1 pandemic.
The company was founded in 1986 by Charles E. Bugg, Ph.D. and John A. Montgomery, Ph.D. In March 1994, BioCryst became a public company when it completed an Initial Public Offering by listing its shares on the NASDAQ stock exchange. In 2008 the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006.
BioCryst is a member of the Alliance for Biosecurity, a group of companies that work to develop vaccines and other measures that can be used in the case of a pandemic or bioterrorism attack.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-01 | Future report Set alerts | |
| Q2 2022 | 2022-08-04 | -0.32 | -0.32 |
| Q1 2022 | 2022-05-05 | 0.00 | 0.00 |
| Q4 2021 | 2022-02-23 | 0.00 | 0.00 |
| Q3 2021 | 2021-11-03 | -0.33 | -0.33 |
| Q2 2021 | 2021-08-05 | 0.00 | 0.00 |
| Q1 2021 | 2021-05-06 | -0.36 | -0.36 |
| Q4 2020 | 2021-02-25 | -0.34 | -0.34 |
| Q3 2020 | 2020-11-05 | -0.26 | 0.00 |
| Q2 2020 | 2020-08-06 | -0.24 | -0.24 |
| 2016-07-06 | Reiterated Rating | FBR & Co | Buy | $6.00 |
| 2016-06-01 | Upgrade | Jefferies Group | Hold to Buy | $14.00 |
| 2016-05-09 | Reiterated Rating | HC Wainwright | Buy | $10.00 |
| 2016-03-09 | Reiterated Rating | FBR & Co. | Outperform | |
| 2016-03-09 | Reiterated Rating | FBR & Co | Outperform | |
| 2016-02-26 | Reiterated Rating | Noble Financial | Buy | $8.00 |
| 2016-02-25 | Reiterated Rating | HC Wainwright | Buy | $10.00 |
| 2016-02-11 | Reiterated Rating | HC Wainwright | Buy | $24.00 to $10.00 |
| 2016-02-10 | Reiterated Rating | Noble Financial | Buy | $21.00 to $8.00 |
| 2016-02-09 | Downgrade | Jefferies | Buy to Hold | $14.00 to $2.00 |
| 2016-02-09 | Lower Price Target | Rodman & Renshaw | Buy | $24.00 to $10.00 |
| 2016-02-09 | Boost Price Target | FBR & Co. | Outperform | $6.00 to $18.00 |
| 2016-02-09 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $16.00 to $5.00 |
| 2016-02-09 | Downgrade | Jefferies Group | Buy to Hold | $14.00 to $2.00 |
| 2016-02-08 | Downgrade | Needham & Company LLC | Buy to Hold | |
| 2016-02-08 | Downgrade | Piper Jaffray | Overweight to Neutral | $15.00 to $5.00 |
| 2016-02-08 | Downgrade | Piper Jaffray Cos. | Overweight to Neutral | $15.00 to $5.00 |
| 2016-01-13 | Lower Price Target | JMP Securities | $17.00 to $14.00 | |
| 2016-01-12 | Reiterated Rating | FBR & Co. | Outperform | |
| 2016-01-06 | Upgrade | Jefferies Group | Hold to Buy | $10.00 to $14.00 |
| 2015-11-11 | Downgrade | Bank of America | Neutral to Underperform | $12.00 to $10.00 |
| 2015-11-11 | Downgrade | Bank of America Corp. | Neutral to Underperform | $12.00 to $10.00 |
| 2015-11-10 | Reiterated Rating | Oppenheimer | Market Perform | |
| 2015-11-10 | Reiterated Rating | Oppenheimer Holdings Inc. | Market Perform | |
| 2015-11-06 | Lower Price Target | JPMorgan Chase & Co. | Overweight | $18.00 to $16.00 |
| 2015-10-15 | Lower Price Target | Jefferies Group | Hold | $12.00 to $10.00 |
| 2015-10-12 | Reiterated Rating | Noble Financial | Buy | |
| 2015-10-09 | Reiterated Rating | FBR & Co. | Outperform | $18.00 |
| 2015-10-09 | Downgrade | Banc of America Sec | Buy to Neutral | |
| 2015-10-09 | Reiterated Rating | HC Wainwright | Buy | $24.00 |
| 2015-10-09 | Downgrade | Bank of America | Buy to Neutral | $16.00 to $12.00 |
| 2015-10-08 | Reiterated Rating | Piper Jaffray | Buy | $18.00 |
| 2015-09-08 | Initiated Coverage | Jefferies Group | Hold | $12.00 |
| 2015-08-11 | Reiterated Rating | Piper Jaffray | Overweight | $18.00 |
| 2015-08-10 | Reiterated Rating | MLV & Co. | Buy | $15.00 |
| 2015-06-30 | Upgrade | Bank of America | Neutral to Buy | $12.00 to $19.00 |
| 2015-05-13 | Reiterated Rating | Oppenheimer | Market Perform | |
| 2015-04-20 | Initiated Coverage | FBR & Co. | Outperform | $18.00 |
| 2015-04-20 | Upgrade | Bank of America | Underperform to Neutral | $8.00 to $12.00 |
| 2015-03-31 | Set Price Target | Needham & Company LLC | Buy | $15.00 |
| 2014-12-22 | Set Price Target | MLV & Co. | Buy | $15.00 |
| 2014-12-15 | Reiterated Rating | Noble Financial | Buy | |
| 2014-12-09 | Lower Price Target | JPMorgan Chase & Co. | Overweight | $20.00 to $18.00 |
| 2014-12-04 | Lower Price Target | Bank of America | Underperform | $9.00 to $8.00 |
| 2014-08-08 | Initiated Coverage | JPMorgan Chase & Co. | Overweight | $20.00 |
| 2014-06-23 | Upgrade | Wells Fargo & Co. | Market Perform to Outperform | $19.00 to $17.00 |
| 2014-06-23 | Upgrade | Wells Fargo | Market Perform to Outperform | $19.00 to $17.00 |
| 2014-05-30 | Boost Price Target | HC Wainwright | Buy | $21.00 to $24.00 |
| 2014-05-28 | Boost Price Target | Roth Capital | $18.00 to $20.00 | |
| 2014-05-28 | Reiterated Rating | Bank of America | Positive | |
| 2014-04-14 | Initiated Coverage | Brinson Patrick | Outperform | $15.00 |
| 2014-03-10 | Initiated Coverage | HC Wainwright | Buy | $21.00 |
| 2014-03-04 | Reiterated | MLV & Co | Buy | $9 to $15 |
| 2014-03-04 | Boost Price Target | MLV & Co. | Buy | $9.00 to $15.00 |
| 2014-02-28 | Initiated Coverage | Oppenheimer | Market Perform | |
| 2014-02-20 | Initiated Coverage | Piper Jaffray | Overweight | $17.00 |
| 2014-02-20 | Initiated Coverage | Mizuho | Buy | $23.00 |
| 2014-02-18 | Initiated Coverage | Needham & Company LLC | Buy | $14.00 |
| 2014-01-28 | Downgrade | Bank of America | Neutral to Underperform | $9.81 to $9.00 |
| 2014-01-27 | Downgrade | Wells Fargo & Co. | Outperform to Market Perform | |
| 2014-01-27 | Downgrade | Wells Fargo | Outperform to Market Perform | |
| 2014-01-21 | Initiated Coverage | Roth Capital | Buy | $18.00 |
| 2014-01-13 | Reiterated Rating | JMP Securities | Market Perform | |
| 2013-12-19 | Reiterated | MLV & Co | Buy | $6.50 to $9 |
| 2013-12-19 | Boost Price Target | MLV & Co. | Buy | $6.50 to $9.00 |
| 2013-11-12 | Upgrade | Bank of America | Underperform to Neutral | |
| 2013-07-25 | Reiterated | MLV & Co | Buy | $3 to $6.50 |
| 2013-04-09 | Upgrade | MLV & Co | Hold to Buy | $3 |
| 2012-08-14 | Downgrade | WBB Securities | Buy to Hold | $8.50 to $4.40 |
| 2011-02-11 | Reiterated | JMP Securities | Mkt Outperform | $15 to $10 |
| 2010-09-29 | Upgrade | Rodman & Renshaw | Mkt Perform to Mkt Outperform | $7 |
| 2010-01-29 | Initiated | WBB Securities | Buy | $8.50 |
| 2009-10-13 | Initiated | JMP Securities | Mkt Outperform | $15 |
| 2008-01-25 | Reiterated | Caris & Company | Average | $8 to $4.50 |
| 2007-11-12 | Reiterated | Caris & Company | Average | $9.50 to $8 |
| 2007-09-20 | Downgrade | Caris & Company | Above Average to Average | $13 to $9.50 |
| 2007-09-17 | Reiterated | Caris & Company | Above Average | $10 to $13 |
| 2007-08-10 | Reiterated | Caris & Company | Above Average | $9.50 to $10 |
| 2016-07-06 | Reiterated Rating | FBR & Co | Buy | $6.00 |
| 2016-06-01 | Upgrade | Jefferies Group | Hold to Buy | $14.00 |
| 2016-05-09 | Reiterated Rating | HC Wainwright | Buy | $10.00 |
| 2016-03-09 | Reiterated Rating | FBR & Co. | Outperform | |
| 2016-03-09 | Reiterated Rating | FBR & Co | Outperform |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In BCRX 159 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Vanguard Group, Inc | 13.84M |
| BlackRock Inc. | 13.77M |
| BAKER BROS. ADVISORS LP | 12.71M |
| STATE STREET CORP | 9.40M |
| venBio Select Advisor LLC | 9.05M |
| FMR LLC | 5.71M |
| Fisher Asset Management, LLC | 5.16M |
| VICTORY CAPITAL MANAGEMENT INC | 3.52M |
| BlackRock Fund Advisors | 3.40M |
| GEODE CAPITAL MANAGEMENT, LLC | 3.37M |
| Artisan Partners Limited Partnership | 2.65M |
| BNP Paribas Investment Partners S.A. | 2.28M |
| Partner Fund Management, L.P. | 2.16M |
| BlackRock Institutional Trust Company, N.A. | 2.08M |
| TWO SIGMA ADVISERS, LLC | 2.02M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| BAKER BROS. ADVISORS LP | 13.13% (9418390) | ACAD / AQXP / BCRX / GHDX / IDRA / INCY / MRTX / SGEN / XOMA / |
| Stonehouse Jon P President & CEO | 0.91% (655092) | BCRX / |
| BAKER FELIX | 0.20% (145533) | ACAD / BCRX / GEVA / GHDX / MRTX / SGEN / |
| STAAB THOMAS R II Senior Vice President and CFO | 0.19% (137383) | BCRX / |
| Cohen Fred E | 0.17% (119410) | BCRX / CDNA / FPRX / GHDX / ROKA / TNDM / VCYT / |
| Babu Yarlagadda S VP Drug Discovery | 0.15% (108871) | BCRX / |
| Barnes Alane P VP, General Counsel & Corp Sec | 0.12% (85768) | BCRX / |
| Jensen Peder | 0.08% (60000) | ACOR / BCRX / FPRX / |
| Hutson Nancy J | 0.05% (38147) | BCRX / CBST / ENDP / |
| McCullough David VP | 0.03% (24124) | BCRX / |
| INGRAM ROBERT ALEXANDER | 0.03% (18902) | BCRX / CREE / EW / REGN / VRX / |
| Sheridan William P SR VP - CMO | 0.03% (18058) | BCRX / |
| SANDERS CHARLES A | 0.02% (12971) | BCRX / BIOD / LPDX / |
| LEE KENNETH B JR | 0.01% (10252) | ARLZ / BCRX / POZN / |
| ABERCROMBIE GEORGE B | 0.01% (10000) | BCRX / OCRX / THRX / ZIOP / |
| LOWREY ROBERT S Controller, PAO | 0.01% (9766) | BCRX / MGT / |
| Powell Lynne Senior VP - CCO | 0.01% (8605) | BCRX / |
UM